Trials / Approved For Marketing
Approved For MarketingNCT02762591
Expanded Access of Pimavanserin for Patients With PD Psychosis
Expanded Access Program of Pimavanserin in Patients With Parkinson's Disease Psychosis
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- ACADIA Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- —
Summary
The purpose of this program is to provide patients with PDP access to pimavanserin until the product receives marketing approval from the FDA and is commercially available.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pimavanserin tartrate | Pimavanserin tartrate 40 mg, tablet, taken as two 20 mg tablets, once daily by mouth |
Timeline
- First posted
- 2016-05-05
- Last updated
- 2017-04-18
Source: ClinicalTrials.gov record NCT02762591. Inclusion in this directory is not an endorsement.